My Ultimate Sign-in System Made Me Invincible

”Your mandate has three primary components,” the Director continued. ”First, clinical observation, which is documenting what you witness on the medical floor within your designated access scope, the monitoring data you are given real-time access to, and the interactions between staff and volunteers that you are permitted to observe. Second, geographic equity verification — confirming that the volunteer pool reflects the distribution commitment made in the public announcements, specifically the fifteen percent regional cap, and that the distribution holds in practice rather than only on paper. Third, framework documentation — recording how the trial’s consent procedures, data privacy protocols, and withdrawal rights function in practice against what was publicly stated.”

She looked at Stein. ”The legal documentation is the component with the longest reach. What you write in those observation notes becomes part of the institutional record from which any future international health law framework for off-world medical research will eventually be constructed. That work doesn’t exist yet. You are contributing to its foundation.”

Stein had her copy of the observer framework open with forty-two marked lines. She had been thinking about the jurisdictional gap since the observer confirmation announcement had named the WHO. ”We are being asked to evaluate a trial we have no authority over, conducted in a location no international body has jurisdiction over, by an organization that has demonstrated it operates on its own terms regardless of external frameworks.” She looked up. ”What is the institutional position on that?”

”The institutional position,” the Director of Health Systems said, ”is that our presence there is more valuable than our absence, and that the documentation we produce has more long-term impact than any authority we could theoretically assert and practically not enforce.” She held Stein’s gaze. ”We are not pretending we have leverage we don’t have. We are using the access we were given.”

The head of Mental Health and Substance Use had been quiet until now. ”The mental health volunteer categories concern me more than any other aspect of the trial,” she said. ”Treatment-resistant PTSD. Major depressive disorder. Substance use disorders. These are conditions where outcome measurement is not objective in the way that spinal cord regeneration is objective. A volunteer walking after a complete spinal cord injury is an unambiguous result. A volunteer reporting improvement in treatment-resistant depression is a more complex picture. What does the monitoring data look like for those cases? How does the system measure neurological intervention? We don’t know, and we won’t know until you’re in that room watching it happen.”

”Which is precisely why your background informs this delegation,” the Director said. ”Document what you see without filtering it through frameworks that don’t apply. If the monitoring data for a mental health case shows you something you can’t interpret with existing tools, write down exactly what you saw and bring it back. The interpretation happens here, with time and with the full picture.”

Dr. Sorensen looked at the geographic distribution section of the briefing document. ”The volunteers from regions with historically limited healthcare access — when we observe their outcomes, we are potentially watching the first demonstration of what this technology does for populations the existing medical system has largely failed. That observation has implications that extend well beyond this trial.” He set the document down. ”I want to make sure the delegation’s reporting gives that appropriate weight.”

The briefing continued for two hours. Each department head worked through the aspects of the trial most relevant to their mandate. Questions were asked and answered where answers existed, and the Director was consistent about the ones that didn’t.

At the end, she looked at the three delegates across the table.